Format

Send to

Choose Destination
Radiother Oncol. 2015 Oct;117(1):159-64. doi: 10.1016/j.radonc.2015.07.018. Epub 2015 Jul 30.

Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer.

Author information

1
Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA.
2
Department of Biomedical Informatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA.
3
Gastrointestinal Tumor Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA.
4
Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA. Electronic address: Javier.TorresRoca@moffitt.org.
5
Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA. Electronic address: Ravi.Shridhar@moffitt.org.

Abstract

BACKGROUND AND PURPOSE:

Adjuvant radiation therapy for resectable pancreatic cancer remains controversial. Sub-populations of radiosensitive tumors might exist given the genetic heterogeneity of pancreatic cancers. We evaluated whether RSI is predictive of survival in pancreatic cancer treated with radiation.

MATERIALS AND METHODS:

We identified 73 genomically-profiled pancreas cancer patients treated with upfront surgery between 2000 and 2011 (48 radiation, 25 no radiation). Briefly, RSI score is derived from the expression of 10 specific genes and a linear regression algorithm modeled on SF2 of 48 cancer cells. The primary endpoint was to assess the association of RSI with overall survival.

RESULTS:

Median follow-up was 67months for surviving patients. On multivariate analysis, patients with radioresistant tumors had a trend toward worse survival (Hazard ratio [HR] 2.1 [95% CI 1.0-4.3], p=0.054). Among high-risk, irradiated patients (positive margins, positive lymph nodes, or a post-operative CA19-9 >90; n=31), radiosensitive patients had significantly improved survival compared with radioresistant patients (median 31.2 vs. 13.2months; HR 0.42 [0.19, 0.94], p=0.04). Among irradiated patients (n=48), low-risk patients lived longer than both high-risk patients with radiosensitive tumors and radioresistant tumors (HR 2.7 [1.0, 7.2], p=0.04 and HR 6.3 [2.3, 17.0], p<0.001, respectively).

CONCLUSIONS:

Integrating RSI with standard high-risk variables has the potential to refine the classification of high-risk resected pancreatic cancer patients treated with radiation therapy.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01754623.

KEYWORDS:

Cancer; Pancreas; Radiation; Radiosensitivity; Surgery; Survival

PMID:
26235848
DOI:
10.1016/j.radonc.2015.07.018
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center